Alvotech (ALVO)
(Delayed Data from NSDQ)
$11.94 USD
+0.03 (0.25%)
Updated Jul 19, 2024 04:00 PM ET
After-Market: $12.02 +0.08 (0.67%) 7:58 PM ET
2-Buy of 5 2
C Value F Growth F Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
ALVO 11.94 +0.03(0.25%)
Will ALVO be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for ALVO based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ALVO
Are Medical Stocks Lagging Alvotech (ALVO) This Year?
Here's Why You Should Consider Buying Alvotech (ALVO) Stock
ALVO: What are Zacks experts saying now?
Zacks Private Portfolio Services
TEVA Stock Rises 135% in a Year: What's Driving the Recovery?
Dr. Reddy's (RDY), Alvotech Unite for Prolia & Xgeva Biosimilar
ScPharmaceuticals, Inc. (SCPH) Reports Q1 Loss, Lags Revenue Estimates
Other News for ALVO
STADA and Alvotech launch Uzpruvo, the first approved ustekinumab biosimilar to Stelara, across Europe
Alvotech Launches First Stelara Biosimilar in Europe
Alvotech Announces Closing of Private Debt Financing
Alvotech Announces Positive Topline Results from Confirmatory Patient Study for AVT03, a Proposed Biosimilar for Prolia® and Xgeva®
Alvotech Issues New Shares to Holders of Convertible Bonds